Athira Pharma Corp (ATHA) - Forward P/E Multiple

Official company branding of Athira (ATHA)

The neuromedicine sector is currently undergoing a strategic review phase, and Athira Pharma, Inc. (ATHA) is restructuring its expenses to focus on rare pathologies following the failures of its primary drug. The business relies on the development of small molecules to restore neural connections in Alzheimer's, minimizing risks through a unique approach to brain regeneration. The forward P/E multiple of the business demonstrates valuation dynamics, where the current parameter equals 0.00.

ATHA - Athira Pharma Market Cap to Projected Earnings over the range 07/04/2022 - 01/12/2026

Analytical breakdowns for Athira Pharma, Inc.

- current price and projected stock value:
Fundamental valuation:ATHA Athira Pharma
Brand item of athira.com

For the high R&D-cost biotech sector of Athira Pharma, Inc. (ATHA), investments in academic staff and the fight against Alzheimer's disease make the valuation of future earnings critically important. Analyzing the history of the company's forward P/E ratio allows for a comparison of market value against expected net income, revealing whether the asset is overbought or if its long-term scientific and technological potential is undervalued.

Competitor analysis for Athira Pharma, Inc.

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Neurogene Inc. - Price to Future Earnings Ratio|acimmune.com - Projected Price to Earnings|Forward P/E Multiple Voyager Therapeutics Inc VYGR|NMRA - Future Price to Earnings|Forward Price to Earnings Multiple Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Future Price to Earnings|Price to Future Earnings Ratio ACOG|Future Price to Earnings Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings SAVA (Cassava)|Market Cap to Projected Earnings Assertio Therapeutics|Coya Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - Forward P/E Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Projected Price to Earnings|CRVO (CervoMed, Inc.) - Projected Price to Earnings|Projected Price to Earnings Alterity Therapeutics Ltd|Future Price to Earnings Clene Inc.|PepGen Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings JUNS (Jupiter Neurosciences Inc)|Future Price to Earnings RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Projected Price to Earnings|Market Cap to Projected Earnings Grace Tx (GRCE)|fireflyneuro.com - Forward P/E Multiple|Klotho Neurosciences (KLTO) - Projected Price to Earnings|NeuroSense Therapeutics, Ltd. (NRSN) - Future Price to Earnings|Price to Expected Earnings Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - Forward P/E Multiple|NRXS: Future Price to Earnings Multiple|Forward P/E Multiple HSDT|Forward P/E Multiple Passage Bio Inc. (PASG)|Future Price to Earnings bionomics.com.au NEUP|Forward P/E Multiple Minerva Neurosciences Inc NERV|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)